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Abstract
RNA interference (RNAi) involves the specific repression of the translation of a
gene through mRNA degradation. Its application has been extended to a variety
of studies both in vitro and in vivo. The Ber-Ab/ translocation is the cytogenetic
marker for chronic myelogenous leukemia (CML) and has been studied
extensively. The K-562 cell line possesses the Ber-Ab/ fusion gene and has been
established as a model for RNAi. lmatinib mesylate (Gleevec) is a proven
specific inhibitor of the Bcr-Abl tyrosine kinase. The aim of this study was to
combine K-562 cells primed with short inte,rfering RNA (siRNA) targeting the Ber

Abl fusion site with treatment with Gleevec. Two different preparations of siRNA:
homogenous-synthetic Ber-Ab/ and heterogeneous-transcribed-digested Ber-Ab/
were used to silence the Ber-Ab/ fusion gene. The synthetic siRNA consisted of a
homogenous mixture of 21nt long double stranded RNA duplexes specific for the

Ber-Ab/ fusion site. The transcribed-digested Ber-Ab/ siRNA were generated
using an in vitro transcription method producing a 450 bp cloned fragment with
the Ber-Ab/ fusion site in the center of the cloned region. This cloned fragment
was further digested with RNAse I' ll to produce a heterogeneous mixture of Ber

Abl 19-21nt siRNA duplexes. We demonstrated a 70% down-regulation of the
Ber-Ab/ mRNA through real time PCR and RT-PCR as well as a 75% down
regulation of the Bcr-Abl and Bcl-xL proteins in K-562 cells transfected with
synthetic Ber-Ab/ siRNA. The ICso of Gleevec alone in the K-562 subline F 1 was
lowered from 0.2µM to 0.06µM in cells transfected with both preparations of Ber

Abl siRNA, while no effect was observed in an irrelevant siRNA control. This
Vl1

suggests an additive relationship between Gleevec and Bcr-Ab/-specific-siRNA
treated cells. An increase in apoptosis was also seen in K-562 cells primed with
Ber-Ab/ siRNA and treated with Gleevec indicating the additive relationship
between Gleevec and Ber-Ab/ siRNA. These results indicate that priming K-562
cells with Ber-Ab/ siRNA correlate with a decrease in the effective dose of
Gleevec required to inhibit the Bcr-Abl protein.
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Chapter 1
Review of the Literature

Introduction
RNA interference (RNAi) is a pathway that targets specific transcripts and
results in gene-specific silencing (1-9). The ability to .target and interfere with
specific RNA has been used in a variety of studies ranging from gene modulation
to screening for specific gene function and disease intervention (10-13). The
potency and efficacy of RNAi surpasses other known methods of transcriptional
down-regulation such as antisense and has a longer sustained effect of
transcriptional repression (14-16). Recently, focus has been placed on the
delivery of RNAi, for which there have been significant advances making the
application of RNAi attainable for both in vitro and in vivo applications (17, 18).
RNAi promises to revolutionize genetics by providing the ability to knock down
the expression of any gene (19, 20).
In chronic myelogenous leukemia, (CML) the molecular marker of
malignancy is the presence of the breakpoint-cluster-region/Ableson (Ber-Ab/)
oncogene (21-23). This marker is not present in normal cells and the Abl
transcript and polypeptide are highly restricted in their expression (24).
Therefore, the Ber-Ab/ fusion gene is an ideal target for RNAi analysis and
therapy (25, 26). The K-562 cell line is a CML derivative that expresses high
levels of the Ber-Ab/ fusion gene, making it a rigorous model for in vitro studies of
1

RNAi (27). To date, various forms of RNAi have been applied in vitro in studies
using various cell lines, including K-562 (28-31).
lmatinib mesylate (Gleevec) is a specific tyrosine kinase inhibitor that
targets the Bcr-Abl oncoprotein (32-37). It has had success used as a clinical
therapeutic agent for CML (36). Bcr-Abl confers resistance to apoptosis; thus,
inhibition of Bcr-Abl with agents such as Gleevec renders cells susceptible to
apoptosis (37, 38). Gleevec has been shown to inhibit the proliferation of K-562
cells and, eventually, lead to differentiation, apoptosis and cell death in vitro (34,
37, 39). Gleevec shows synergism when administered in conjunction with a
number of different agents, including interferon-a, etoposide, and daunorubicin in
K-562 cells (40, 41). This observation supports the focus of this study, which is to
investigate possible synergistic effects of the combination of with Bcr-Abl-RNAi
with Gleevec using K-562 cells. Thus, targeting the protein substrate-binding S'ite
of the Bcr-Abl protein in tandem with the Ber-Ab/ transcript provides two separate
methods of inhibition for the same molecular target.
Chronic Myelogenous Leukemia
Chronic myelogenous leukemia (CML) presents with elevated levels of
myeloid and erythroid cells in peripheral blood and with marked myeloid
hyperplasia in the bone marrow (21). The disease exhibits three phases: the
chronic phase, lasting 3 to 5 years; the accelerated phase, with marked
hypermetabolism and intramedullary expansion of leukemic cells; and blast
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crisis, confirmed by greater than 30% blasts in the peripheral blood and/or bone
marrow (42).
CML is a clonal hematopoietic malignancy identified by the Philadelphia
(Ph) chromosome, which is found in 95% of CML patients (22, 43). The Ph
chromosome results from the t(9q34;22q11) translocation, where the 5' end of
the Abelson (c-ab/) gene from chromosome 9 is relocated onto the 3' end of the
Breakpoint cluster region (c-bc1' gene on chromosome 22 in a head to tail
manner (43).The Ph chromosome was the earliest specific chromosome
rearrangement identified in a malignancy and has been cloned and characterized
at the molecular level (23, 44). The cytogenetic evolution pattern correlates with
the clinical behavior of a disease (44).

Bcr-Abl Fusion
The t(9q34;22q11) translocation results in the chimeric gene, Ber-Ab/,
which is transcribed into an 8.5 kb hybrid mRNA, and translated into the Bcr-Abl
fusion protein (Figure 1) (45). The breakpoint in the Ab/ gene can occur
anywhere within the 300kb 5'end of the gene, upstream of the first alternative
exon lb, between exons lb and la, or downstream of exon la (46). In contrast, the
vast majority of CML patients possess a breakpoint in the Ber gene within a
5.8kb region known as the major breakpoint cluster region (M-bc1', spanning 5
exons from exons 12 to 16, referred to as b1 to b5 (24, 46-48).
The Bcr-Abl fusion protein is a constitutively activated cytoplasmic tyrosine
kinase of 210 kD, 902 amino acids in length, and is complexed in vivo with both

3
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Figure 1. The Bcr-Abl fusion protein. The origin of the Bcr-Abl
fusion protein, the Philadelphia chromosome, results from the
translocation of c-Bcr from chromosome 22 onto c-Abl located on
chromosome 9 in a head to tail manner.
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p160 Ber and ph-P53 proteins (21, 49, 50). Protein tyrosine kinases are
members of a group of enzymes that bind ATP and catalyze the transfer of the y
phosphate to the hydroxy group of a tyrosine residue on a protein (32). The
phosphorylated substrates can then serve as binding sites for other substrates,
carrying out the signal transduction cascade of a variety of pathways (32).
Many intracellular pathways are directly affected by the expression of the
Bcr-Abl protein (Figure 2) (51). The substrates targeted by Bcr-Abl include CRKL,
p62Dok, paxillin, CBL and RIN, which are integral in pathways involving Pl3kinase, Akt, ERK JUN kinase, MAP, Myc, STAT, and Ras/Raf (21, 52-54). Bcr
Abl initiates the Ras/Raf/MEK/ERK, JAK/STAT, Pl3K/Akt signal transduction
pathways, resulting in cell proliferation (51, 55, 56).

Ber-Ab/ fusion in hematopoietic cell lines abrogates their dependency on
growth factors for proliferation and survival (54). The constitutive tyrosine kinase
activity of the nascent Bcr-Abl oncoprotein provides the transforming ability (57,
140). The expression of Bcr-Abl in mice induces a disease similar to CML, which
corroborated the role of Bcr-Abl as a transforming agent of malignancy (50).
Although the role of the Ber gene is not fully understood, it is expressed
ubiquitously, with the highest mRNA levels found in the brain and hematopoietic
cells (24). Ber protein levels are elevated in the early stages of myeloid
differentiation,

and

levels

dropped

significantly

as

cells

mature

to

polymorphonuclear leukocytes (24). The Ber protein has also been linked to
cytoskeletal reorganization, and DNA repair (24). While the intracellular role of
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Figure 2. Bcr-Abl pathway interactions. The expression of Bcr-Abl
modulates the Ras/Raf, P13K, Jak/STAT and MEK/ERK pathways,
leading to multiple proliferative and antiapoptotic outcomes. Bcr-Abl
activation follows the binding of the oligomerization domain in the
Ber protein onto the tyrosine kinase region of the Abl protein. The
Abl protein then phosphorylates Tyr1 n in the Ber protein leading to
proliferation.
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Ber has not been determined in normal cells, its suggested function in CML cells
is as a negative regulator of Bcr-Abl kinase activity (58). The removal of the
oligomerization domain,

the first 63 amino acid residues of the Ber

serine/threonine kinase, results in a truncated Ber moiety . resistant to
autophosphorylation by the activated Abl tyrosine kinase and limited transforming
ability (24, 57, 58). This truncated Ber protein strongly inhibits the Bcr-Abl kinase
activity (58). Arlinghaus et al. demonstrated Bcr-Abl inactivating normal Ber
through phosphorylation (58). This observation supports the role of the activated
Ber kinase as inhibiting the Bcr-Abl kinase and asserts the function of Bcr-Abl as
deactivating the Ber serine/threonine kinase, propagating the deregulation of the
Bcr-Abl tyrosine kinase activity (58). The normal function of the Abl protein is
primarily as a tyrosine kinase, and Abl is differentially phosphorylated during the
cell cycle (24, 59, 60). Abl associates with cell cycle proteins Rb, p53, p73, Atm,
and cyclin D and overexpression of Abl leads to growth arrest (24, 45). Since
normal cells lack the Bcr-Abl fusion protein, it represents a selective site for
intervention (32).

K-562 Cell Line
The K-562 cell line is an undifferentiated leukemic line derived from the
plural effusion of a CML patient in blast crisis (61, 62). These cells were first
observed to maintain their Philadelphia chromosome positive, Ph (+), status
through 175 serial passages over 3 ½ years (61). In 1975, 1-4 Ph chromosomes
were detected in each cell (61). Several atypical Ph chromosomes, common in
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K-562 cells, result in an increased amount of Bcr-Abl oncogene expression (27,
63). When compared to standard patient samples, K-562 cells were reported to
have a 82-fold overproduction of the Bcr-Abl transcript in 1994 and a 200-fold
overproduction of the Bcr-Abl transcript in 1997 (27). In the K-562 cell line, the
fusion site of. the Bcr-Abl gene is between the Ber exons b3 and b4 and between
the Abl exons a1 and a2, resulting in the b3a2 variant (46).

Expression of Bcr

Abl by the K-562 cell line was found to impart resistance to apoptosis induction in
response to various cytotoxic drugs or serum deprivation (52).

Gleevec
STl-571 (imatinib mesylate, or Gle�vec) (Figure �) is a Ber-Ab/- specific
tyrosine kinase inhibitor (32, 64). Gleevec has been termed the "gold standard" in
treatment of chronic myelogenous leukemia due to its specificity (36, 65, 66). The
Bcr-Abl protein is a cytosolic tyrosine kinase that does not depend on ligand
binding and subsequent receptor dimerization for activation (32). This aspect of
Ber-Ab/ results in an inability to modulate its activity with receptor-based

inhibitors (32). The limited sequence variation surrounding the ATP-binding site,
as well as the conformational differences between inactive and active forms of
kinases, offer sources for inhibition (67). Gleevec works as an ATP-competitive
inhibitor of the Ber-Ab/ kinase activity (32). From the crystal structure, it was
shown that Gleevec binds to c-Abl via a series of H-bond interactions and van
der Waals contacts with specific amino acid residues (32). Mutations in these
amino acids result in resistance to Gleevec (32). While Gleevec is a potent
8

STl-571 (a.k.a. imatinib or Gleevec® )
Figure 3. Structure of Gleevec. imatinib mesylate or Gleevec has a
relative molecular mass of 589.7 with a molecular formula of C29H31N10
• CH4SQ3 and a chemical formula 4-[(4-Methyl-1-piperazinyl) methyl]-N
[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl] amino]-phenyl] benzamide
methanesulfonate. Figure from Novartis (32).

9

competitive inhibitor of c-Abl, and also interferes with c-Kit and PDGFR-J3, it is
inactive against any other tyrosine kinases (32).
In vitro studies of Gleevec, using Bcr-Abl-expressing cell lines including
K-562, have demonstrated an antiproliferative effect (33, 68, 69). Gleevec kills
leukemic cells in vitro and in vivo through an apoptosis-mediated mechanism (34,
68, 70). Apoptosis was detected measuring caspase 3 activity and the release of
cytochrome c from the mitochondria, which are both hallmarks of apoptosis (34,
68, 71). The apoptotic mechanism that Gleevec triggers involves the downstream
inactivation of the Bcl-2 family protein, Bcl-xL (34, 39, 72). This protein is also
constituitively activated through autophosphorylation by Bcr-Abl (39). Oetzel et
a/. showed that Gleevec caused the downregulation of Bel-XL, resulting in
susceptibility to programmed cell death, while there was no change in the level of
Bcl-2 (34). Gleevec also mediated a decrease in Akt kinase activity and an
increase in the Apo-2L/TRAIL-induced apoptosis of K-562 cells (73).
Although Gleevec has specificity and efficacy, the required length of the
treatment, which may be extended for the length of a person's life, can result in
the development of resistant clones (73-76). There is evidence of a number of
mechanisms responsible for the development of Gleevec-resistant CML clones,
such as increased production of the Bcr-Abl transcript number, increases in the
expression of the Bcr-Abl protein, point mutations in the ATP binding pocket or
other functional sites, and increased drug efflux (32, 74, 77-80).
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Gene Silencing
Gene silencing is defined as the silencing of the translation of a specific
gene (19, 81). This concept has been applied successfully both in vitro and in
vivo (1, 2, 10, 18, 19, 82). Antisense technology has been applied over the past
decade with some-success (14, 83, 84). Antisense interference involves either
antisense DNA (oligodeoxynucleotides, ODN) or RNA homologous to the specific
region of the mRNA (14). These ODNs are transfected into cells and
subsequently hybridize to the specific region within a particular mRNA transcript
(14). This binding inhibits translation of the message (14). Antisense interference
is related to RNAi, which also specifically targets mRNA (14, 85). It is noteworthy
that the stability of single-stranded antisense ODNs is considerably less than that
of double stranded RNA, which results in less efficient silencing (28).
New evidence supports multiple functions for gene silencing in a variety of
biological processes, including antiviral defense, embryonic development, and
maintenance of genomic stability (86-89). Gene silencing is referred to as RNAi
in animals, post-transcriptional gene silencing (PTGS) or co-suppression in
plants and quelling in fungi (86, 90, 91). Although the processes share some
similar steps and result in specific targeting of mRNA, there are distinctive
differences in the proteins involved, the length of the effect, and the ability to
exhibit gene repression (6, 10, 19, 92). While the silencing effect is pronounced
in mammals, normal gene expression generally returns in 9 to 11 days (5).
The phenomenon of PTGS was first discovered in plants over a decade
ago and involves specific targeting of a gene and degradation of the mRNA
11

resulting in a block in translation of the protein encoded by the silenced gene (1,
93). The process of PTGS is believed to have co-evolved with its viral antagonist
to function as a primitive immune response against the invasion of foreign nucleic
acids presented through viral infections and transposons and retroposons (3).
This theory is supported by the observation that certain viruses are able to
overcome or prevent mRNA degradation by expressing proteins that suppress
PTGS (5). Most plant viruses possess single-stranded RNA genomes, which are
replicated by the virus-encoded RNA-dependent RNA polymerase to produce
both sense and antisense strands of RNA (19). These strands have the potential
to hybridize to form double-stranded RNA (10). Once dsRNA, a marker for viral
infection, is detected in the cell, the process of PTGS is initiated (1 0).
The first proposed mechanism to explain RNAi was set forth by Bass and
was based on the introduction of dsRNA directly into cells to be degraded and
used in gene silencing (94). Bass proposed that the dsRNA introduced into the
cell is, in turn, targeted by an endonuclease which then cleaves 1it to short, -23nt,
dsRNA, also referred to as short interfering RNA (siRNA), which bind to and
promote degradation of the free mRNA (94). This endonuclease, later termed the
Dicer enzyme, is a member of the Argonaute protein family (95). It is an initiator
of the formation of a 3-protein complex known as the RNA-induced silencing
complex (RISC) with the siRNA for mRNA degradation (95).
The first animal application for this technique came in Caenorhabditis
elegans where it was discovered that, as in the plant system, gene down
regulation could be heritable due to the presence of the enzyme, RNA-dependent
12

RNA polymerase (RdRp) (2, 96). The plant and C. elegans mechanism are
similar in that dsRNA has catalytic silencing capabilities, while single stranded
RNA gets degraded upon delivery into the cell (2) . The mechanism by which
plants and nematodes undergo gene silencing has been referred to as the
"guide- primer" model ,

(Figure 4) where the Dicer enzyme cleaves double

stranded RNA to make short interfering (siRNA) (92). The Dicer enzyme unwinds
the si RNA, and the antisense strand of the siRNA duplex binds to the
homologous region of mRNA (92). These si RNAs serve as a guide-primer with
RdRp to convert the mRNA into double stranded RNA to be digested by the
Dicer enzyme (92) . This process is propagated indefi nitely due to the recycling of
the template siRNA and the stability of both the RdRp and Dicer enzymes (92).
The assertion that siRNAs are catalytic in nature is supported by the requi rement
of only a few si RNA molecules to mount a sufficient RNAi response (6, 97).
The mammal ian model for gene silencing has been termed the
"endonucleocytic-cleavage" model (Figure 5), which involves a group of proteins
known as the RNA-induced silencing complex (RISC) (2, 92, 93, 98). The
proteins included in the mammalian RISC are EIF2C2, Gemin3 and Gemin4, and
an endonuclease, Slicer, activated by a helicase domain located on the Dicer
enzyme (95, 98) . This activation results in the unwinding of the double-stranded
si RNA, leavi ng the antisense strand of RNA bound to the activated RISC
complex (92). This siRNA serves as a template for sequence-specific targeted
degradation of mRNA (92, 94). The "endonucleocytic cleavage" model proposes
that the activated RISC complex binds the single-stranded mRNA template to be
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Figure 4. The "guide-primer'' model. The guide-primer mechanism for
gene silencing begins with the cleavage of double-stranded RNA into
si RNA by the Dicer enzyme, Panel A, followed by the unwinding of the
siRNA duplex by a helicase domain in Dicer. The antisense strand of
the siRNA duplex then binds to the mRNA in a sequence-specific
manner, Panel B. The binding of the siRNA initiates the RNA
dependent RNA polymerase (Panel C), which generates double
stranded RNA to be cleaved by Dicer, Panel D. This process is
propagated through the generation of more siRNA and continues
unabated until the specific mRNA has been degraded. Adapted from
Schwarz et al. (92).
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Figure 5. The "endonucleocytic-cleavage" model. The D.
melanogaster and mammalian model for gene silencing is
referred to as the "endonucleocytic-cleavage" model. The
"endonucleocytic cleavage" model of gene silencing involves the
RISC complex forming with th� siRNA duplex. Double-stranded
RNA is digested with Dicer, Panel A. The si RNA duplex is
unwound by a hel icase in the Dicer enzyme and activates the
RISC complex, Panel B. The activated RISC binds mRNA in a
sequence-specific manner (Panel C) and i s cleaved by an
endonuclease in the activated R ISC complex. Adapted from
Scwartz et al. (92).
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cleaved and regenerates the Slicer endonuclease with its siRNA (Figure 5) (92,
94, 99). This process continues unabated until the mRNA has been degraded
(92). The protein-endonuclease/siRNA complex co-purifies, indicating the
stability of the complex (98).
The length of the dsRNA is integral to the RNAi response initiated by the
cell (4, 100, 101). In an experiment designed to test the relevance of dsRNA
length, Elbashir et al co-transfected a number of different cell lines with a
luciferase-reporter plasmid and 0.21 µg of siRNA or a longer dsRNA duplex (4).
They observed siRNA specifically targeted the luciferase reporter gene, while the
longer dsRNA duplexes strongly and nonspecifically reduced the reporter gene
expression (4). The nonspecific reduction of reporter gene expression was
attributed to an interferon response mounted by the cell against the dsRNA (4,
100, 101). The length dependence of 21-23 mer formation is thought to be a
mechanism to prevent the undesired activation of RNAi by intramolecular base
paired, non-pathogenic RNA structures (5). The location of the siRNA sequence
homology is imperative for the success of the silencing effect and a single base
pair mismatch can result in up to a 10% difference in efficacy (29, 102-104).
The range of RNAi applications for cancer include drug discovery,
treatment, abolishing drug resistance, and cell cycle regulation (105-110).
Similarly, RNAi has been explored both in CML and in Ph-positive cell lines in an
attempt to silence the Ber-Ab/ oncogene (25, 26, 28, 29, 31, 111-113). Since
normal cells lack the Ber-Ab/ fusion gene, it provides a prime molecular target for
RNA interference (25, 26, 28, 29, 105, 106, 114, 115). The efficacy of targeting
16

this translocation has proven successful in a number of RNAi studies and this
treatment has been effectively applied in both peripheral blood CML cel ls in vitro
and a n umber of Ph-positive cell lines, including the K-562 cell line (28 , 29, 1 1 3,
1 1 4). The long half-life of the Bcr-Abl protei n, which is greater than 48 hours, has
posed a problem in molecular therapies that target the Bcr-Abl gene (1 5, 1 1 7).
This problem has been overcome using various methods desig ned to sustain the
antisense or siRNA within the cell longer than 48 hours (30, 1 1 8) .

Apoptosis
Apoptosis (programmed cel l death) is the result of a sequence of events
leading to the suicide of a cell (Fig ure 6) (1 1 9). Its function is vital to an organism
and is essential in normal cel l turnover, development of the immune system,
embryonic development, metamorphosis, and hormone-dependent atrophy
(1 20) . The apoptotic mechanism of death occurs in two distinct phases: a
commitment to cell death , followed by an execution phase, where standard
morphological and biochemical changes occur ( 1 20). Some of the standard
characteristics of apoptotic cell death are condensation and fragmentation of the
nuclear chromatin, compaction of the cytoplasmic organelles, dilation of the
endoplasmic reticulum, decreasing cell volume, and alterations to the cell
membrane resulting in the recognition and phagocytosis of apoptotic cells, which
prevents an inflammatory response (1 20). The apoptotic process can be in itiated
by a variety of cellular insults including DNA damage, and cytotoxicity ( 1 2 1 ) . It
can also be induced in the cell by intracellular factors such as the up-reg ulation
17

DNA Damage,
cytotoxicity

\

Figure 6. Apoptotic pathway. Overview of apoptotic pathway
shows DNA damage and cytotoxic agents leading to activation of
caspases 8 and 1 0. This triggers the mitochondrial membrane
potential col lapse to release cytochrome c, which is inhibited by
Bel-XL. Cytochrome c results in activation of caspases 3 and 7
and leads to cel l death.
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of either tumor necrosis factor or p53 (122). The consequence of the apoptosis
pathway is the death of a cell without an inflammatory· response (119). The
apoptosis cascade consists of a variety of proteins, such as caspases, and
members of the Bcl-2 protein family (120, 123). To date, mammalian cells have
been reported to have 12 caspases present in the zymogen, the inactive form, to
prevent accidental cell death (124). Caspases are present in three types: the
initiators, the executioners, and the inflammatory caspases (1 24). The initiators,
caspases 2, 8, 9 and 10, begin the death cascade, where, through a system of
biochemical signals

originating

from either extracellular or intracellular

environment, the executioner caspases, 3, 6, 7, are activated (124).
The sequence of events during apoptosis begins with the death signal,
from either the extracellular environment, or the intracellular matrix (124). The
membrane proteins TRAIL, TNF-R1, Fas, or Perforin can all receive and transmit
this death signal (125). Caspases 2, 8, and 10 are then activated and proceed to
initiate the collapse of the mitochondrial membrane (120). The collapse of the
mitochondrial membrane leads to the release of cytochrome c into the cytosol
(126). The activity of caspases 3 and 7 is promoted by the presence of
cytochrome c in the cytosol (126). Caspase 3 is the primary executioner caspase
and has been shown to cleave and activate the DNA fragmentation factor (OFF),
resulting in the DNA fragmentation step in apoptosis (126). Proteins that function
in promoting apoptosis are Bax, Bak, Bad, and Bcl-xs, among others (127).
Proteins that serve to inhibit this process include Bcl-2, Bcl-xL, and Akt, among
others (126, 127).
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It has been discovered that Bcr-Abl serves as a negative regulator of a
number of apoptotic pathways (51 ). One pathway for this regulation is through
the inhibition of the release of mitochondrial cytochrome c and other pre
apoptotic mitochondrial events (126). This interference results in caspase 3
remaining inactive and the inhibition of apoptosis (126). Protection from
apoptosis is achieved through Bcr-Abl initiating two mechanisms: constitutive
activation of STATS, and suppression of SHI P1 expression, resulting in elevated
levels of phosphatidylinositol (3,4,5)-triphosphate (24). Constitutive activation of
STATS subsequentially leads to the upregulation of the antiapoptotic protein Bel
XL (39, 128, 129). Bcl-xL prevents perforation of the mitochondrial membrane, by
functioning as an antagonist of the Bax-Bak heterodimer (124). This inhibition of
Bax-Bak prevents the release of cytochrome c and other apoptotic promoters
(124). The Bcl-xL/Bax-Bak interaction is corroborated by the inhibition of Bcr-Abl
resulting in the down regulation of Bcl-xL (39, 72). This down-regulation induces
cell differentiation and leads to apoptosis through a number of death-inducing
agents ( 1 26, 1 29-1 33). The proposed interaction of Bcr-Abl with STATS, involves
the Tyr

1 77

residue of Bcr-Abl, which shares homology with the tyrosine

phosphorylation site of STATS (128). Down-regulation of STATS abrogates Bcr
Abl-dependent protection from apoptosis and leukemogenesis (128).
Based on this review of the literature it was hypothesized that targeting
both the Bcr-Abl oncogene and protein using RNA interference and Gleevec in
the K-562 cell line would result in restoration of apoptosis sensitivity.
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. Chapter 2
Materials and Methods

Cel l Culture
K-562 cells, subline F 1 , were passaged weekly in Eagle's minimal
essential medium supplemented with 15% fetal bovine serum (FBS) (GIBCO
BRL, Grand Island, NY), plus nonessential amino acids with an inoculum of 1 .5 x
°

104 cells/ml (134). The cultures were incubated at 37 C in 5% CO2. K-562 cells
from 1 0 ml cultures were pelleted, the supernatants removed, and the pellets
resuspended in 10 ml RPMI 1640 medium supplemented with L-glutamine, 10%
°

FBS, and Gentamicin (800µg/ml) (Sigma, St. Louis, MO) at 37 C in 5% CO2.

Proliferation
MTT assay
Mitochondrial

function

was

assayed

colorimetrically

through

the

conversion of the substrate, MTT (3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide) (Sigma, St. Louis, MO). Reactions, 0.5ml, were performed
°

in 24-well plate where K-562 cells (subline F1) were incubated with at 37 C with
5% CO2 for two hours in the presence of 500µg/ml MTT. The cells were
centrifuged at 1 4,000 x g for 5 minutes and the supernatant removed. The cells
were lysed by vortexing in 700µ1 2-propanol for 5 minutes. Equal aliquots were
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assayed in quadruplicate on a 96-well plate with a propanol blank read by an
EL340 microplate reader (Biotek, Winooski, VT) at a wavelength of 570nm with a
background subtraction of 630-690nm (135).

3

[

H]-thymidine incorporation assay
Incorporation of tritiated thymidine ([3H]-thymidine) (ICN, Newport Beach,

CA) was assayed using 0.25µCi in 50µ1 complete RPMI 1640 media. 100µ1 K562 cells (subline F1) suspended in complete RPMI 1640 media were co-cultured
with 50µ1 tritiated thymidine in quadruplicate for 4 hours at 37°C with 5% CO2.
The cells were harvested with a cell harvester (Skatron Instruments, Inc. ,
Sterling, VA) and radioactivity was assayed at counts per minute (cpm) in a
Packard (Downer's Grove, IL) liquid scintillation analyzer (136).

Apoptosis
Mitochondrial Membrane Potential Assay
To measure apoptosis, two different methods were used : 1) measurement
of loss . of the mitochondrial membrane potential (137) 2) measurement of the
activity of the caspase 3 enzyme (138). The JC-1 bi-fluorescent dye was used to
measure apoptosis by flow cytometry. The green, monomeric dye is absorbed
into the mitochondria in healthy cells and reaches a critical concentration where it
then aggregates and emits red light. The loss of the red signal is the measure of
apoptosis. K-562 cells were pelleted at 2200 , x g for, 10 minutes and the
...,';.� C
supernatant removed. The cells were then resuspended in 1ml PBS, [137mM
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NaCl, 2.7mM KCI, 10mM Na-PO4, pH 7.4] (lnnoGenex, San Ramon, CA) in the
presence of 5µg/ml JC-1 bi-fluorescent dye (Molecular Probes, Eugene, OR) with
°

vigorous pipetting and incubated on a rocker at 37 C with 5% CO2 for 20
minutes. The cells were centrifuged at 2000 x g for 5 minutes and the
supernatant removed. Cells were washed twice with 1ml of PBS and centrifuged
at 2000 x g for 5 minutes and the supernatant removed. The cells were
resuspended in 500µ1 PBS and a total of 10,000 events were assayed using flow
cytometry. As cells progressed into apoptosis, the early depolarization of the
mitochondria was a reliable qualitative method for identifying programmed cell
death (137).

Caspase 3 Assay
To measure caspase 3 activity, K-562 cells were pelleted at 2200 x g for
10 minutes and lysed with 100µ1 lysis buffer (Chemicon, Temecula, CA). 20µ1
total protein lysate was then incubated with caspase 3 substrate (ac-DEVD-pNA)
(Oncogene, La Jolla, CA) in quadruplicate on a 96 well plate for 6 hours. The
caspase 3 activity was measured at a wavelength of 405nm on an EL340
microplate reader (Biotek). As the cells underwent apoptosis, the caspase 3
activity increased (138).

Cloning
siRNA synthesis for RNAi involves cloning, isolation and amplification of
the region of interest, and the subsequent processing of this region into siRNA.
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This site-specific siRNA is then inserted into the cell through transfection using
cationic liposomes and the silencing effect is then assayed through various
methods including protein quantification, and mRNA degradation. To generate
siRNA, the Ber-Ab/ fragment was first cloned into the Litmus 28 plasmid vector
(New England Biolabs, Beverly, MA).

Pri mer Design
Primers specific for Bcr-Abl oncogene were designed according to
sequence data from the NCBI BLAST database. The sequences used in the
design of Ber-Ab/ specific primers were identified by accession numbers Y00661
(Human bcr mRNA) and X1 641 6 (Human c-abl mRNA). The Bcr-Abl forward
(SS) strand primer begins at base 31 66 with the break point located 21 2 bp
downstream at base 3378. The Bcr-Abl reverse (AS) strand primer begins at
base 468 with the breakpoint located 241 bp upstream at base 227. The resultant
PCR product is 453 bp long with the fusion site located approximately in the
center of the strand. PCR primers were also designed to flank the T?/polylinker
region for verification of positive colonies. Primers were made by Sigma Genosys
(Midland, TX).

Bcr-Abl Pri mer Sequence
Forward (SS): 5'-ggagggagaacatccgggagcagc-3' - position (31 66-31 90)
Reverse (AS): 5' -gccatttttggtttgggcttcacag-;3' � position (468-443)
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RNA isolation
K-562 cells were centrifuged at 2200 x g for 10 minutes and the media
was removed. The cells were then lysed with 1ml TRlzol (lnvitrogen, Carlsbad,
CA) transferred to 1.5ml sterile tubes and 200µ1 chloroform was added (139).
The Chloroform/TRlzol cell lysate was vortexed and then centrifuged at 12,000 x
g for 5 minutes. The upper aqueous phase was then removed and transferred to
a new tube and an equal volume of acidic (pH 4.6) phenol/chloroform (1:1) was
added. The tubes were shaken and centrifuged at 12,000 x g for 5 minutes and
the upper layer was transferred to a new tube. The phenol/chloroform extraction
was repeated two times. Sodium acetate, pH 5.2, (1:10 volume), 100% ethanol
(two volumes), and 10µ1 (5mg/ml) linear acrylamide carrier (Ambion, Austin, TX)
was added and incubated at -80°C for 1 hour. RNA was centrifuged at 14,000 x g
for 10 minutes and the supernatant removed. The pellet was washed with 80%
ethanol twice, air-dried for 5 minutes, and resuspended in nuclease-free water.
For storage, 1.5µ1 RNAse antibody (1 :20 volume) was added to prevent
degradation during storage. RNA was quantified on a UV spectrophotometer at
260nm and quantified using the Beer-Lambert law, O. D./260 x 40µg/ml x dilution
factor

=

RNA concentration in µg/ml.

Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Once the total RNA was purified, the mRNA served as a template in the
RT-PCR reaction to generate cDNA. 1.5µ1 (2µg/µI) RNA was added to 2.5ng/µI
random hexamer, 1 µM Ber-Ab/ reverse antisense primer, 1.5µ1 nuclease-free
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water to a total volume of 4µ1 . The reaction mixture was placed on a heating
°

block pre-warmed to 65 C for 2 minutes, then placed on ice. In a separate tube,
reverse transcriptase, thermoscript (0.75 units/µI), superscript II (10 units/µI), and
superscript Ill (10 units/µI) were used, and RNAse- out (2 units/µI) was added to
5µ1 2X reaction buffer to a total volume of 6µ1 (lnvitrogen, Carlsbad, CA). The
reaction mix was combined with the RNA/primer mix to create a total reaction
°

volume of 10µi'. The reaction was incubated at 25 C for ten minutes to allow for
°

primer hybridization, and then transferred to a water bath at 56 C for 90 minutes.

Polymerase Chain Reaction (PCR)
The cDNA generated from the RT-PCR was subjected to Ber-Ab/ gene
specific primer amplification through PCR. The initial reactions were done in 16µ1
total volume and later reactions were scaled up to 50µ1. For the 16µ1 reaction, 8µ1
2X PCR Buffer with Enhance component (1ml buffer mix = 200µ1 10X PCR
Buffer, 400µ1 5X Enhance, 40µ1 10mM dNTP mix, 360µ1 nuclease-free water),
Taq DNA Polymerase (0.02 units/µI) (Eppendorf, Westbury, NY), 4µ1 cDNA
template, 1.25µM Ber-Ab/ forward (SS) and reverse (AS) primers, 2µ1 nuclease
°

free water. The reaction conditions were as follows: 97 C initial denaturation for 2
°

°

°

minutes followed by 35 cycles at 94 C for 1 minute, 55 C for 1 minute, 72 C for 2
°

minutes and ended with an extension at 72 C for 7 minutes. The samples were
°

°

then held a� 4 C, analyzed on an agarose gel and stored at -20 C for later usage.
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Real Time PCR
The real time reactions using the QuantiTect gene expression assay
system (Qiagen, Gaithersburg, MD) were assembled in triplicate as follows:
master mix [12.5 µI 2X QuantiTect probe RT-PCR master mix, 2.5 µI 10X
QuantiTect assay mix (probes were specific for Ber-Ab/ and GAPDH) , 0.25 µI
QuantiTect RT mix, 4.75 µI RNAse free water] and 5 µI template RNA (diluted
1 :50 and 1: 100) to a total reaction volume of 25 µI. The cycle parameters were:
reverse transcription for 30 minutes at 50 ° C; PCR initial activation step of 95 ° C
for 15 minutes; 3 step cycling: denaturation 15 s at 94 °C, annealing/detection 30
s at 56 ° C, extension 30 s at 76 ° C; cycles were repeated for 45 cycles. Standards
were made for both Ber-Ab/ and for GAPDH through a series of dilutions of RNA
to concentrations of 250ng/5µI , 100ng/5µI, 25ng/5µI, 10ng/5µI , 1ng/5µ1. These
standards were used to quantify the levels of Ber-Ab/ and GAPDH expression of
the experimental groups.

EcoRV Digestion
To prepare the Litmus 28i vector (New England Biolabs, Beverly, MA) for
cloning, the vector was digested with EcoRV at a site in the polylinker located
between two opposing T7 promoters. The digestion protocol was as follows:
EcoRV (1 units/µI, Promega, Madison, WI), BSA (0.001µg/µI , Promega), 4µ1 NEB
Buffer 3 (New England Biolabs), Litmus 28i plasmid vector (25ng/µI, New
England Biolabs), 29.6µ1 molecular grade water to a total reaction volume of
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°

40µ1. The digestion mixture was incubated at 37 C for 2 hours, followed by
°

°

incubation at 25 C for 2 hours, and a final heat inactivation at 80 C for 20
minutes. The linearized vector was confirmed on a 1 % agarose gel and then
°

stored at -20 C for later usage. This digestion yielded a blunt, linearized vector
suitable for cloning.

Kienow Fragment/T4 Polyn ucleotide Kinase Reaction
·To prepare the Bcr-Abl oncogene fragment for cloning into the Litmus 28i
plasmid vector, the fragment was digested with Kienow fragment for blunt end
polishing. The digestion protocol was as follows: Bcr-Abl fragment (37.2ng/µI),
1 0µI 2X Quick Ligation Buffer (New England Biolabs), dNTP (465µM,
Eppendorf), Kienow fragment (0.0465 units/µI, New England Biolabs) to a total
°

reaction volume of 21 .5µ1 . The Kienow reaction was incubated at 25 C for 1 5
°

minutes and then heat killed at 75 C for 20 minutes. This reaction was
supplemented with 850µM ATP and T4 polynucleotide kinase (0.4 units/µI, New
°

England Biolabs) and incubated at 37 C for 30 minutes. The T4 polynucleotide
°

kinase reaction was then heat inactivated at 65 C for 20 minutes. The final
concentration of the modified Ber-Ab/ oncogene fragment was determined to be
40ng/µI on a 2% agarose gel.
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Ligation of Ber-Ab/ into Litmus 28i Plasmid Vector
Ligation reactions were assembled in two different reactions of
vector: insert ratios, 1 :3 and 1 :4. The 1 :3 vector: insert reaction was as follows:
Litmus 28i plasmid vector (20ng/µI), Ber-Ab/ (10ng/µI) oncogene fragment insert,
Quick DNA Ligase (0.2 units/µI, New England Biolabs), and 2X Quick Ligation
Buffer (New England Biolabs) to a total volume of 5.5µ1. The 1 :4 vector: insert
reaction was as follows: Litmus 28i plasmid vector (18.5ng/µI), Bcr-Abl oncogene
fragment insert (12.5ng/µI), Quick DNA Ligase (0.15 units/µI, New England
Biolabs), and 2X Quick Ligation Buffer (New England Biolabs) to a total volume
of 6.5µ1. To verify the presence of Bcr-Abl insert-positive Litmus 28i plasmids, the
ligation reaction was digested with EcoRV to eliminate the background and then
subjected to PCR with the Litmus 28i specific primers flanking the site of insertion
into the vector.

Transformation of Ligation into Competent E. coli Cells
In a sterile 5ml tube, 2.5µ1 of the ligation reaction digested with EcoRV
was incubated with 25µ1 Nova Blue competent cells (Novagen, Madison, WI) on
°

ice for 30 minutes. The cell/ligation mix was then heat shocked at 42 C for
1minute and then placed on ice for 2 minutes. 150µ1 of prewarmed SOC media
°

was added to the cell/ligation mix and incubated at 37 C, shaking at 225rpm for 1
hour. The cells were then plated onto prewarmed LB agar plates with 100µg/ml
°

Carbenicillin (lnvitrogen), and incubated at 37 C overnight. Five colonies were
selected and tested through PCR ampl ification with the Litmus primers. Positive

29

colonies were grown overnight, plasmid preps were made for siRNA generation
°

and glycerol stocks were prepared and stored at -80 C. These positive clones
were sequenced to verify accuracy of the sequence as compared to the
published BLAST data.

siRNA Generation
Double-stranded DNA was obtained through the PCR of the Litmus
28i/Bcr-Abl as well as the Litmus 28i/LitMal insert with T7 primers under these
°

conditions: 97 C initial denaturation for 2 minutes followed by 35 cycles at 94 °C
°

°

for -1 minute, 55 C for 1 minute, 72 C for 2 minutes and ended with an extension
°

°

at 72 C for 7 minutes, holding at 4 C. DNA was then subjected to T7 RNA
Polymerase amplification to generate double stranded RNA. The reaction
protocol was as follows: template DNA (1OOng/µI), 2µ1 1OX Reaction Buffer, 8µ1
NTP mix, 2µ1 T7 RNA ' Polymerase (Ambion), and nuclease-free water to a total
°

reaction volume of 20µ1. The reaction was incubated at 37 C for 2 hours followed
by a digestion with DNAse 1 and RNAse A to eliminate the DNA template and
single stranded RNA. The digestion protocol is as follows: 20µ1 T7 RNA
Polymerase reaction, 21 µI nuclease free water, 5µ1 1OX Digestion Buffer, DNAse
1 (0.8 units/µI), and RNAse A (40pg/µI) to a total reaction volume of 50µ1, was
°

incubated at 37 C for 1 hour. The product was column purified, quantified with
A2so and analyzed on a 1.5% agarose geL The final step in generating the siRNA
involved the digestion of the double-stranded RNA with RNAse Ill as follows:
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dsRNA (300ng/µI), 5µ1 10X RNAse I l l Buffer, RNAse I ll (0.3 units/µI, Ambion),
and nuclease-free water to a total reaction volume of 50µ1. The RNAse 1 1 1
°

digestion reaction was incubated at 37 C for 1 hour and the siRNA were column
purified and quantified with A2so and analyzed on a 12% polyacrylamide gel.

Transfection
Transfection was carried out with varying molar concentrations of siRNA
with a set amount of RNAifect (Qiagen). Transfection protocol was as follows: in
a sterile PCR tube siRNA was diluted in RPMI 1640 media, 10% serum (Atlanta
Biologicals) with gentamicin to a total volume of 100µ1. RNAifect, 10µg/ml, at a
ratio of 6µI :1µg siRNA was added to 100µ1 siRNA mix and incubated at room
temperature for 25 minutes to allow for complex formation. After formation, the
complex was then added to the K-562 cells suspended in 100µ1 RPMI 1640
media, 10% FBS, with gentamicin in a 24-well plate in a total transfection volume
°

of 200µ1 to transfect for 4 -10 hours at 37 C with 5% CO2. Upon completion of the
transfection, the cells were then added to 10ml flasks with RPMI 1640 media,
with 10% FBS and Gentamicin (80µg/ml) and grown for the duration of the
°

experiment at 37 C with 5% CO2.

Western Blot
K-562 cells were pelleted at 2,200 x g for 5 minutes and the supernatant
removed. The cells were lysed in Chaps Cell Extract Buffer [50mM Pipes/NaOH
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(pH 6.5), 2mM EOTA, 0.1% Chaps, 5mM OTT, 20 µg/ml Leupeptin, 10 µg/ml
pepstatin, 10 µg/ml aprotinin, and 1mM PMSF] for 30 minutes on ice. The lysate
was centrifuged at 14,000 rpm for 10 minutes and the supenatant transferred to a
new tube. Protein concentration was quantified using Bradford analysis on an
EL340 microplate reader (Biotek) and 65µg total protein used in western blot
assay.
The protein was loaded into a 6%

SOS

denaturing gel and

electrophoresed at 125V for 1½ hours. The protein was transferred onto a
nitrocellulose membrane at 70V at 4 °C for 1 hour. The nitrocellulose membrane
was blocked using casein for 1 hour. Primary antibodies: a-rabbit Ber (Santa
Cruz Biologicals, Santa Cruz, CA), a-rabbit Bcl-xL (Spring Bioscience, Fremont,
CA) dilutions of 1:1000 in casein, was applied on nitrocellulose membrane at 4 °C
overnight with shaking. The membrane was washed 3 times for 5 minutes in
TBST and the secondary antibody, a-rabbit lgG conjugated with horseradish
peroxidase (dilution of 1 :5000 in casein), was applied to the membrane with
shaking for 1 hour. The membrane was washed 5 times for 5 minutes in TBST
and the substrate was applied for 5 minutes. The protein was visualized using X
ray film.
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Chapter 3
Results

Gleevec
Proliferation was measured using two independent assays, MTT salt
conversion, which quantified the loss of mitochondrial membrane potential, and
[

3

H]-thymidine uptake, which determined the level of DNA synthesis. Both of

these proliferation studies were set up to establish the ICso, where 50% viability
was present, of Gleevec was established in the F1 subline of K-562 cells.
Through a series of time-course, dose response experiments performed in
triplicate over the course of three weeks, the average of all the proliferation data
was compiled into a dose response curve of Gleevec. From these averages the
IC50 was determ ined. Time points were taken at 24, 48, 72, and 96 hours to
determine the optimal time for assaying the effects of Gleevec; the data from
times 24 hours and 96 hours was not included. In both the MTT and the [3 H]
thym idine uptake experiments, the ICso of Gleevec was found to be 0.2 µM
(figures 7 and 8). Both time points 48 and 72 hours were used for later studies.
The next study measured the level of apoptosis in response to the stress
of Gleevec through both caspase 3 activity and loss of mitochondrial membrane
potential. In this study the empirical IC5o found through proliferative measure was
corroborated by apoptosis experiments to confirm that the decline in proliferation
was, in fact, due to programmed cel l death.
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Figure 7. The ICso of Gleevec determined by MTT reduction.
An average of 3 weeks data (n = 9) of the K-562 sub line F 1 co
cultured with varying doses of Gleevec assayed at 48 and 72
hours indicated the ICso of Gleevec to be 0.2µM.
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Figure 8. The ICso of Gleevec determined by [3 H]-thymidine
uptake. An average of 3 weeks data (n = 9) of the K-562 subline
F1 co-cultured with varying doses of Gleevec assayed at 48 and
72 hours indicated the I C 50 of Gleevec to be 0.2µM.
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Caspase 3 activity is shown to be elevated as a response to increasing
doses of Gleevec at 48 and 72 hours (Figures 9 and 1 0). There was baseline
caspase 3 activity up to 0.2 µM, but doses beyond this resulted in a greater than
5-fold increase in caspase 3 activity at both 48 and 72 hours. The mitochondrial
membrane integrity measured by FACS analysis is shown in response to
Gleevec stress at 48 and 72 hours (Figures 1 1 and 1 2). With doses above 0.2
µM, Gleevec induces a greater than 5-fold increase in apoptotic cells at 48 hours,
and a greater than 20-fold increase in apoptotic cells at 72 hours.
Proliferative decline was determined to be a result of apoptosis as [3 H]
thymidine data at 48 and 72 hours was co-plotted with caspase 3 data at 48
hours and 72 hours (Figures 1 3 and 1 4). This inverse relationship shows 0.2 µM
Gleevec as the effective dose at both inducing apoptosis and reducing viability by
50%. These findings corroborate the previously published Gleevec I Cso of
0.25µM (34, 35).

The Ber-Ab/ fusion gene was cloned into the Lit 28 RNA transcription
vector (Figure 1 5) used to in vitro transcribe double-stranded RNA for making
siRNA to be used later in the study. The blunt, non-directional method of cloning
was chosen because the orientation was irrelevant. The Ber-Ab/ fusion gene
product, 450bp, and the Lit28i vector was gel purified and prepared for ligation
(Figure 1 6). To measure the success of the reaction, the ligation product was
digested with EcoRV and subjected to PCR (Figure 1 7) . This digestion limited the
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Caspase 3 Activity at 48 Hours
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Figure 9. Apoptosis measured by caspase 3 activity at 48 hours.
Apoptosis determined by caspase 3 activity in the K-562 subline
F1 co-cultured with varying doses of Gleevec assayed at 48
hours indicated that doses greater than 0.2µM induced
apoptosis.
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Caspase 3 Activity at 72 Hours
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Figure 10. Apoptosis measured by caspase 3 activity at 72
hours. Apoptosis determined by caspase 3 activity in the K-562
subline F 1 co-cultured with varying doses of Gleevec assayed
at 72 -hours indicated that doses greater than 0.2µM induced
apoptosis.
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Mitochondrial Membrane Potential at 48 hours
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Figure 1 1 . Mitochondrial membrane potential at 48 hours. The
K-562 subline F1 co-cultured with varying doses of Gleevec
indicated that doses greater than 0.2µM induced apoptosis at
48 hours.
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Mitochondrial Membrane Potential at 72 hours
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Figure 12. Mitochondrial membrane potential at 72 hours. The
K-562 sub line F 1 co-cultured with varying doses of Gleevec
indicated that doses greater than 0.2µM induced apoptosis at
72 hours.
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Figure 13. Apoptosis and proliferation at 48 hours.
Apoptosis and proliferation co-plotted against dose of
Gleevec at 48 hours indicated that the decline in
proliferation was attributed to apoptotic cell death. The
two lines intersect at 0.3µM Gleevec.
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Figure 1 4. Apoptosis and proliferation at 72 hours.
Apoptosis and proliferation co-plotted against dose of
Gleevec at 72 hou rs indicated that the decline in
proliferation was attributed to apoptotic cel l death.
The lines intersect at 0.3µM Gleevec.
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LITMUS 28i

T7J.
Bgl I I
(Nsi 1) - Ppu 1 0 I
Bss H I I
Bsi W I
Xho I
Eco R I
(Pst I)
Eco R V ...,___�er-Ab I

Barn H I

Ori

pLITM US TII
2.8 kb

Hind I l l
Nco l
(Aat I I)
Age I
Xba I
Avr II
(Sac I)
(Kpn l) - Acc 65 I
Stu I

T7i
Figure 15. The Litmus 28i plasmid vector. The Litmus 28i
plasmid vector used for in vitro production of siRNA
contains two opposing T7 promoters. The Ber-Ab/ fusion
gene was cloned into the polylinker region at the blunt
EcoRV site.

42

nsertion

450b

Figure 1 6. Purification of the Bcr-Abl PCR product for
cloning . 1 % agarose gel stained with ethidium bromide. PCR
prod uct of BCR-ABL fragment, cut from this gel and then purified
using the Wizard PCR cleanup kit (Promega). Lanes 1 -9 : BCR
ABL fragment 1 (450bp), Lane 1 0 : negative control (no
template), Lane 1 1 : EcoRV d igested Litmus 28i plasmid.
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Figure 1 7. Confirmation of Bcr-Abl positive clones through
PC R. Panel A: Ligation reaction was digested with EcoRV and
PCR confirmed the presence of the Ber-Ab/ insert. Panel B :
Plasmid DNA was isolated , column purified and PCR
confirmed the Ber-Ab/ positive colonies.
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background of the re-ligated vector and allowed for confirmation of the ligation for
procession to the next step of transformation. Following the ligation and the
transformation into competent Escherichia coli cells, five colonies were present.
Of these five colonies, three were found to be positive for the Ber-Ab/ insert
(Figure 17). Through restriction endonuclease digestion, two of the three colonies
were confirmed to be positive for the Ber-Ab/ insert (Figure 18). This step was
confirmed through additional PCR (data not included) and through sequencing
(Figures 19 and 20).
Following the confirmation of the Bcr-Abl insert, the Bcr-Abl-specific siRNA
were made through amplification with T7 RNA polymerase (Figure 21) and
digested with RNAse Ill (140). This product yielded 15-19 nucleotide duplexes
homologous to the 450 bp region of the Bcr-Abl insert. The integrity of these
siRNA is shown in Figure 22.
Transfection at first proved to be a problem and limiting factor in the
knockdown of the Bcr-Abl transcript. Transfection efficiency was measured and
optimized

using

a

non-silencing,

fluorescein-labeled

siRNA

duplex.

Oligofectamine yielded 25% transfection efficiency as measured through flow
cytometry (Figure 23), and was not detectable using fluorescent microscopy.
Delivery the siRNA into the K-562 cel ls was accomplished using RNAifect, with
consistent efficiencies of 90% or better as measured through both flow cytometry
(Figure 23) and fluorescent microscopy (Figure 24). RNAifect transfections were
performed in complete media, whereas Oligofectamine transfections were
performed in the absence of serum and were more cytotoxic.
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422 bp

Figure 1 8. Restriction enzyme digestion. 1 % Agarose gel stained with Ethidium
Bromide. Plasmids 1, 2 and 3 were digested with Hind I l l to confirm orientation,
and then double digested with Xhol and Xbal to confirm the size of the insert.
Lane 1 : plasmid 1 undigested, Lane 2: plasmid 2 undigested, Lane 3 : plasmid
3 undigested, Lane 4: plasmid 1 digested with Hind I l l (422bp), Lane 5:
plasmid 1 double digested with Xhol and Xbal (511bp), Lane 6: plasmid 2
digested with Hind I l l, Lane 7: plasmid 2 double digested with Xhol and Xbal,
Lane 8: plasmid 3 digested with Hind I l l (422bp), Lane 9: plasmid 3 double
digested with Xhol and Xbal (511bp).
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Figure 1 9. Sequence data of Lit28i/Bcr-Abl . Litmus sequencing
primers specific for the Litmus 28 plasmid were used to sequence
DNA spanning the polylinker region including the cloned Ber-Abt
insert. Panel A: includes the start of the Bcr-Abl oncogene as wel l as
the fusion site Pa nel B: includes the end of the Bcr-Abl oncogene.
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Cloned T7 Ber-Ahl Template

T7 promoter
5

Litm us Polylinker Site

'taatacgactcactatagggcagatcttcgaatgccatcgcgcgcaccgtacgtctcgaggaattcctgcag

gggagggagaacatccgggagcagcagaagaagtgtttcagaagcttctccctgacatccgtggagctgcag
atgctgaccaactcgtgtgtgaaactccagactgtccacagcattccgctgaccatcaataaggaagatgatga
gtctccggggctctatgggtttctgaatgtcatcgtccactcagccactggatttaagcagagttcaaaagcccttc
agcggccagtagcatctgactttgagcctcagggtctgagtgaagccgctcgttggaactccaaggaaaacctt
ctcgctggacccagtgaaaatgaccccaaccttttcgttgcactgtatgattttgtggccagtggagataacactct
aagcataactaaaggtgaaaagctccgggtcttaggctataatcacaatggggaatggtgtgaagcccaaacc
aaaaatggc�ctctggtaccctctagtcaaggccttaagtgagtcgtattfccctatagtgagtcgtatta 3'
Litmus Polylinker Site

T7 Promoter

Figure 20. Sequence of Lit28i/Bcr-Abl. The Ber-Ab/ fragment was cloned into
the Litmus 28 vector polylinker site at the EcoRV site. The Ber-Ab/ gene was
sequenced and the red text represents the Ber fragment, and the blue text
represents the Ab/ fragment.
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Figure 21 . Two different preparations of double-stranded
RNA. 1 % agarose gel stained with ethidium bromide. Double
stranded DNA and double stranded RNA generated th rough
PC R and RT-PCR respectively. Lane 1 : PC R DNA product
(5 1 2bp), Lane 2: Negative control (no primers) , Lane 3:
Negative control (no template), Lane 4: dsRNA (NEB) , Lane
5: dsRNA (Ambion), Lane 6: Negative control (no enzyme),
Lane 7: Negative control (no template).
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Figure 22. Quantification and integrity of siRNA. Serial
dilution of double stranded DNA oligo, 20µM stock, used to
quantify and measure the integrity of the siRNA generated
from the NEB and Ambion RNAse I l l enzymes. 12% non
denaturing polyacrylamide gel stained with ethidium bromide.
Lane 1 : 10µ1, 20µM DNA oligo, Lane 2: 10µ1, 10µM DNA
oligo, Lane 3: 10µ1, 4µM DNA oligo, Lane 4: 10µ1, 2µM DNA
oligo, Lane 5: 10µI, 1 µM DNA oligo, Lane 6: 1 0µI Bcr-Abl
NEB RNAse I l l enzyme product, Lane 7: 1 0µI Bcr-Abl
Ambion RNAse I l l enzyme product, Lane 8: 10µ1 Lit28mal
Ambion RNAse I l l enzyme product.
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Figure 23: Transfection efficiency by flow cytometry. Transfection
efficiency as measured using a non-silencing fluorescein conjugated siRNA
duplex through flow cytometry. Panel A: Closed region represents the
untransfected control, open area represents the Oligofectamine transfected
K-562 cells. Oligofectamine yielded a 25% transfection efficiency. Panel B:
Open area represents the untransfected control, the closed green area
represents the K-562 cells transfected using RNAifect. RNAifect yielded a
transfection efficiency of 90%. Both transfection reagents were repeated
several times with similar results.
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A.

B.
Figure 24. Transfection efficiency by fluorescent microscopy.
Fluorescent microscopy, 400X total magn ification, of K-562 cells
transfected with a non-silencing fluorescein-conjugated siRNA
stained with Hoescht 33324. Panel A: fluorescein-conjugated
siRNA, Panel B: untransfected control
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The RNAi effect was measured using three approaches, including serial
dilution of the RNA , real time PCR, and western blotting to measure the
modulation of the Bcr-Abl protein. The lowest detectable Ber-Ab/ transcript
concentration of K-562 RNA was determined through a serial dilution of the RNA
in the RT-PCR reaction. Concentrations of RNA were high enough to show the
presence of the Bcr-Abl transcript product, and low enough to illustrate the
difference between the RNAi treated cel ls and the untreated. The results of this
dilution show that the lowest concentration to visualize the Ber-Ab/ transcript
product on an agarose gel is at 3µg/ml RNA in the RT-PCR reaction (Figure 25).
This dilution series was then applied to K-562 RNA transfected with both
synthetic and transcribed Bcr-Abl-specific siRNA at 48 hours (Figure 26). The
RNAi effect is visible with 5µg/ml RNA in the RT-PCR, where both the
transcribed and the synthetic Ber-Ab/-specific siRNA treated cells have less Ber

Abl transcript than the untreated control. When compared to the irrelevant and
the untreated control in Figure 27, both the synthetic and the transcribed Bcr-Abl
specific siRNA treated cells showed a remarkable drop in the amount of Bcr-Abl
transcript, and no relative change in the Aldolase transcript.
The visible reduction in Ber-Ab/ transcript levels was confirmed to be due
to mRNA degradation using real time PCR to quantify the levels of Ber-Ab/
transcript and the housekeeping gene GAPDH as a control. The synthetic Ber
Abl-siRNA mRNA was silenced 70% and the transcribed-digested Ber-Ab/-siRNA
resulted in a 50% knockdown of the Ber-Ab/ mRNA (Figure 28).
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Bcr-Abl

Figure 25: Bcr-Abl RNA threshold. Serial
d ilutions of total RNA in RT-PCR reactions
establ ished the range of detection of the Ber-Ab/
gene down to 60ng (3µg/ml) template RNA. 1.5%
agarose gel stained with ethid ium bromide Lane
1: 12.5 µg/ml RNA, Lane 2: 6.25 µg/m l RNA,
Lane 3: 3 µg/ml RNA, Lane 4: 1.5 ng RNA, Lane
5: negative reaction control (no template)
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Titration of RNA (µg/m l) i n RT-PC R
to show RNAi Effect at 48 hours

5µg

A.

1 Oµg 20µg 40µg
*·

f .

A

.. ............
.

......,_�

B.
C.
D.
Figure 26. RNAi through RT-PCR at 48 hours.
PCR of titration of RNA in RT-PCR illustrates the
degradation of the Ber-Ab/ mRNA at the 5µg/ml
concentration, 1.5% agarose gel stained with
ethidium bromide. Panel A: untreated, Ber-Ab/
fragment, Panel B: synthetic Ber-Ab/-specific
siRNA (800nM), Ber-Ab/ fragment, Panel C:
transcribed Ber-Ab/-specific siRNA (800nM), Ber
Abl fragment, Panel D: untreated, A/do/ase
fragment
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RNAi Effect at 72 hours
1

2

3

4

A.
B.
Figure 27. RNAi at 72 hours. PCR of RT-PCR
using 5µg/ml total RNA harvested from K-562
cells at 72 hours shows the degradation of Bcr
Abl mRNA, 1 . 5% agarose gel stained with
ethidium bromide. Panel A: Ber-Ab/ frag ment,
Panel B: Aldolase fragment. Lane 1 : untreated ,
Lane 2 : irrelevant siRNA (800nM), Lane 3:
synthetic Bcr-Ab/-specific siRNA (800nM), Lane
4: transcribed Bcr-Ab/-specific siRNA (800nM)
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Bcr-Abl m RNA at 48 hou rs
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Control
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RNAifect
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Synthetic
Bcr-Abl

Transcribed
Bcr-Abl

Figure 28. Real time PCR measuring Ber-Ab/. Real time PCR data
for Ber-Ab/ mRNA of K-562 cells transfected with 4µg siRNA
illustrates that the synthetic Bcr-Abl-specific siRNA reduced the
Ber-Ab/ mRNA of K-562 cells 70% and the transcribed Ber-Ab/
siRNA reduced the Ber-Ab/ mRNA 50%, while the negative
controls show no change of Ber-Ab/ mRNA levels in relation to the
untreated control.
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Using the GAPDH as the housekeeping gene control, there was an
unremarkable difference in the Ber-Ab/ si RNA transfected cel ls compared to the
untreated and the RNAifect negative control (Figure 29) .
The modulation of the Bcr-Abl protein proved to be difficult due to the long
half-life and the high transcript number found in K-562 cells (1 5, 27-29). To
down-regu late the protein two transfections were needed , with one following 24
hours after the initial transfection (29) . Cells were harvested 24 hours after the
second transfection and protein was isolated . The synthetic Bcr-Abl siRNA down
reg ulated the Bcr-Abl protein 80% compared to the irrelevant siRNA control
(Figure 30). The synthetic Bcr-Abl si RNA also down-regulated the Bcl-xL protein
greater than 75% compared to the irrelevant siRNA control, suggesting an
ind uction of apoptosis (Figure 30) .

Combi nation Treatment

Alone, RNAi and Gleevec are effective, respectively, at reducing the
amount of Bcr-Abl mRNA and protein. When combined they show possible
synergism . Proliferation and apoptosis measurements were used to show the
synergistic relationship between RNAi and Gleevec. The initial findings supported
Bcr-Abl-specific siRNA and Gleevec interacting, but the effect was min imal at
800nM siRNA (Figure 3 1 ) . When the higher concentration of 1 .6 µM siRNA was
combined with Gleevec, the RNAi specifically lowered the IC 50 greater than 2-fold
at both 48 and 72 hours compared to the negative control (Figures 32 and 33).
Based on the proliferation dose response cu rve established for Gleevec
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GAPDH m RNA at 48 hours
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Figure 29. Real time PCR measuring GAPDH. Real time PCR
data for GAPDH mRNA of K-562 cells transfected with 4µg siRNA
illustrates that there is little effect on transcription of the
housekeeping gene, GAPDH as a result of transfection with these
siRNA.
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1

2

3

4

Bcr-Ab l

Bcl-xL

Ber
Figure 30. Western Blot of Bcr-Abl and Bcl-xL, Bcr-Abl and
Bcl-xL protein was down-regulated greater than 80% after
two transfections of synthetic Bcr-Ab/-specific siRNA. Ber
was used as a loading control. Lane 1 : RNAifect alone,
Lane 2: Irrelevant siRNA (4µg), Lane 3 : synthetic Ber-Ab/
specific siRNA (4µg), Lane 4: transcribed-digested Bcr-Abl
specific siRNA (4µg)
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Combination Treatment at 72 Hours
1 00
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% Control
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20

0.0
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Gleevec (µM)
- Irrelevant siRNA (800nM)
c:::::::i Synthetic Bcr-Abl siRNA (800nM)
- Transcribed Bcr-Abl siRNA (800nM)

Figure 31 . 800nM siRNA combi nation treatment at 48 hours.
[3 H]-thymidine uptake data for K-562 cells treated with 800nM
siRNA as normalized to the negative control (RNAifect alone) at
72 hours illustrates that as the doses of Gleevec increase, the
synthetic and transcribed-d igested Bcr-Abl siRNA show a decline
in proliferation .
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Combination Treatment at 48 hours

% Control
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-+- Irrelevant siRNA (1 600nM)
Transcribed Bcr-Abl siRNA (1 600nM)
Synthetic Ber-Abt siRNA (1 600nM)

Figure 32. 1 .6µM siRNA and Gleevec combination treatment at 48
hours. [3 H]-thymidine uptake data for K-562 cells treated with 1 600nM
siRNA compared to negative control at 48 hours show a greater than
two-fold decline in proliferation of the cells transfected with Bcr-Abl
specific siRNA compared to those transfected with irrelevant siRNA.
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Combination Treatment at 72 hours
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Figure 33. 1 .6µM siRNA and Gleevec combination treatment at 72
hours. [3 H]-thymidine uptake data for K-562 cells treated with 1 600nM
siRNA compared to negative control at 72 hours show a greater than
two-fold decline in proliferation of the cel ls transfected with Bcr-Abl
specific siRNA compared to those transfected with irrelevant siRNA.
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(Figures 7, 8, 9, and 1 0) the IC 50 was lowered greater than 3-fold . Experiments
were repeated th ree times and points were taken in quadruplicate.
The apoptosis data supports synergism of RNAi and Gleevec. When
functional mitochondria were measured , the level of apoptosis was sign ificantly
greater in K-562 cells transfected with Bcr-Abl specific siRNA and apoptosis was
observed at lower concentrations of Gleevec (Figure 34). These find ings suggest
a correlation with Bcr-Abl si RNA and Gleevec.

64

Combination Treatment Effect
on Apoptosis at 72 hours
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Figure 34. 1 .6µM siRNA and Gleevec treatment induces
apoptosis. Apoptosis was determined by functional
mitochondria assay of K-562 cells co-treated with
1 600nM siRNA and Gleevec presented as percent of
the untreated control at 72 hours.
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Chapter 4
Discussion

RNAi has been established as a means to silence the transcription and
subsequent translation of a gene both in vitro and in vivo (2 , 4, 1 8 , 1 9, 28, 29).
The Ber-Ab/ tra nslocation is a potent transforming agent in leukemogenesis and
many studies have focused on its down-reg ulation (34, 40, 57 , 1 44 ). Studies
involving antisense and RNAi have been effective in down-regulati ng the Ber-Ab/
oncogene in vitro (1 5, 28, 29, 1 1 8). The tyrosine kinase inhibitor, Gleevec, has
proven to be an effective inhibitor of the Bcr-Abl protein (32). In th is study, both
Gleevec and RNAi targeted the Bcr-Abl protein and gene, respectively, allowing
for both upstream and direct modulation of the same molecular target.
Previous stud ies aimed at Bcr-Abl mRNA knockdown have been effective
at abrogating the translation of the Bcr-Abl protein (1 4, 1 5, 1 1 8). The down
reg ulation of the Bcr-Abl mRNA restored sensitivity to apoptosis (1 1 8 , 1 41 ).
Antisense approaches have been effective at down-reg ulating the Ber-Ab/
oncogene in CML primary cells and K-562 cel ls and have been approved for
clinical trials (1 5, 1 1 8, 1 42). Spiller et al. reported significant mRNA tra nscript
reduction using modified antisense ODN specific for the Ber-Ab/ fusion site,
although no cha nge in Bcr-Abl expression was observed (1 5). Protein down
reg ulation was unchanged , probably due to the transient nature and instability of
the ODN as well as the long half-life of the Bcr-Abl protein, wh ich has been
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reported at being greater than 48 hours ( 1 5, 1 1 7). Martiat et al. demonstrated
that the stable expression of the antisense ODN specific for the Ber-Ab/ fusion
site delivered using a retroviral vector in K-562 cel ls resulted in a decline in
proliferation coupled with down-reg ulation of Ber-Ab/ mRNA and protein (1 1 8). A
constant antisense presence resu lted in the Bcr-Abl protein down-regulation.
RNAi offers an alternative approach to repress the translation of a specific
gene, which involves the specific degradation of ta rgeted mRNA ( 1 0, 1 9). Whi le
RNAi approaches differ from antisense in the mechanism of action , both result in
translational inhibition . RNAi has proven successful in knocking down the Ber-Ab/
oncogene, abrogating the prod uction of the Bcr-Ab l protein (28 , 29, 1 1 3). In th is
study, RNAi was selected to inhibit the Bcr-Ab l gene due to the stability of double
stranded si RNA in vitro. Two different siRNA prepa rations were compared to
measure the Bcr-Abl gene knockdown .
The efficacy of siRNA delivery into the targeted cell was critica l, and there
have been several developments aimed at increasing the efficiency of delivery
(1 1 3, 1 43). Initial experiments with Oligofectamine and Lipofectami ne 2000 were
25% and 5% effective, respectively, as measured by the uptake of a non
silencing fluorescein-conjugated si RNA duplex by flow cytometry (Fig ure 22).
These experiments were performed in serum-free media, which could have
contributed to low transfection efficiency. Transfection with RNAifect yielded over
90% siRNA oligonucleotide uptake in the presence of serum and was selected
because the transfection cond itions were most similar to cu lture cond itions
(Figure 22).
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Two Ber-Ab/-specific siRNA preparations spanning the Bcr-Abl fusion site
were compared to evaluate the efficacy of both the synthetic (Qiagen) and
transcribed-digested, which we prepared (28, 29, 140). The transcribed-digested
siRNA were generated from a 450 bp fragment spanning the Ber-Ab/ fusion site,
which yielded a heterogeneous mixture of siRNA, 17-19 nucleotides in length.
The transcribed-digested preparation encompassed more than the homogenous
Bcr-Abl breakpoint-specific synthetic siRNA with the anticipation that it would
offer other sites of gene down-regulation with a single transfection. Ber-Ab/
mRNA

levels were

measured both qualitatively through

RT-PCR

and

quantitatively through real time PCR. The transcribed-digested Ber-Ab/ siRNA
resulted in a 50% down-regulation of the Ber-Ab/ mRNA measured by real time
PCR (Figure 27) and Ber-Ab/ was not detected using RT-PCR. This supported
Yang et al. , who observed significant luciferase gene knockdown using
transcribed-digested siRNA (140). The heterogeneity of our transcribed-digested
Bcr-Abl siRNA proved to be a disadvantage and was not observed to down
regulate the Bcr-Abl protein. The heterogeneity of the transcribed-digested
siRNA could have diluted the effective domains for potent silencing and, as a
result, there were less siRNA specific for regions that would have produced a
greater effect.
Synthetic Bcr-Abl siRNA-transfected cells showed a 70% reduction of Bcr
Abl mRNA, as measured through real time PCR and were undetected using RT
PCR, suggesting a more potent knockdown of the Bcr-Abl mRNA (Figure 27).
These results corroborate Wilda et al. and Scherr et al. , who both reported 70%
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Bcr-Abl mRNA knockdown using synthetic siRNA, and Li et al. , who reported
greater than 90% Bcr-Abl knockdown with shRNA (28, 29, 1 1 3). The synthetic
Bcr-Abl siRNA were also capable of down-regulating both the Bcr-Abl and Bcl-xL
proteins (Figure 29) . Oetzel et al. observed that down-regulation of the Bcr-Abl
protein by Gleevec led to down-regulation of Bcl-xL protein (34). This suggested
that sensitivity to apoptosis had been reversed , as well as underscored the well
defined relationship of Bcr-Abl and Bcl-xL in K-562 cells (34, 39, 57, 1 1 4). As was
observed by Scherr et al. , the synthetic Bcr-Abl siRNA required a second
transfection 24 hours later to down-regulate the Bcr-Abl protein (29). The dilution
of the siRNA through cell divisions and the long half-life of the Bcr-Abl protein
necessitated a second transfection to deliver the siRNA into the newly divided
cells.
Initial studies were focused on determining the proliferative and apoptotic
effects of varying concentrations of Gleevec in K-562 cells. The antiproliferative
effect of Gleevec was attributed to specific inhibition of the Bcr-Abl tyrosine
kinase (32-37). The range where the effect of Gleevec would not mask the effect
of RNAi when combined was determined through a dose-response curve of
Gleevec daily, over 4 days. These initial studies, measured by proliferation
assays in K-562 cells co-cultured with Gleevec, determined the IC 50 to be 0.2 µM
and demonstrated that 48 hours and 72 hours were the optimal times to observe
the antiproliferative effect (Figures 7 and 8). This dose corroborated Buchdunger
et al. who reported 0.25 µM as the IC 50 of Gleevec (35). Time-points were also

taken at both 24 and 96 hours, where results at 24 hours were unremarkable and
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96 reflected an increase in apoptosis. Apoptosis was measured daily over 4 days
in cells co-cultured with Gleevec. Both caspase 3 activity and mitochondrial
membrane collapse were elevated as the concentration of Gleevec increased .
The apoptosis data corroborated 48 and 72 hours as the optimal times to
observe the apoptotic effects of Gleevec in K-562 cells (Figures 9- 1 2) . The
correlation with decline in proliferation and increase in apoptosis suggested that
Gleevec induced apoptosis in K-562 cells (Figures 1 3 and 1 4) . There was no
marked effect in either parameter at 24 hours, and at 96 hours even the control
was showing an increase in apoptosis.
Studies investigating the combination of Bcr-Abl-specific siRNA with
Gleevec involved 3 doses that spanned the I C50 . Proliferation was used to
measure the correlation of siRNA-transfected cells treated with Gleevec because
the initial studies establishing the I C50 measured proliferation. The findings
suggested a correlation between the combination of both synthetic and
transcribed-digested Bcr-Abl-specific siRNA and Gleevec in K-562 cells. The
established Gleevec I C50 was lowered from 0.2µM to 0. 06µM when treated with
4µg (1 .6µM) Ber-Ahl-specific siRNA, and unaffected with 4µg (1 .6µM) irrelevant
Lit28mal siRNA, suggesting an association between Gleevec and Ber-Ab/ siRNA
(Figures 32 and 33). Lower concentrations of siRNA at 2µg {800nM) resulted in a
lesser effect, which suggests that the siRNA act in a concentration-related
manner (Figure 3 1 ). The proposed mechanism for this interaction involves the
degradation of the Ber-Ab/ mRNA, leading to a decrease in the production of the
Bcr-Abl protein as shown in Figure 35. The amount of Gleevec required to inhibit
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the remaining Bcr-Abl protein was reduced because production of the protein had
been inhibited . An increase of apoptosis in cells transfected with both Ber-Ab/
specific siRNA and treated with Gleevec was greater than the level of apoptosis
observed in cells treated with Gleevec alone (Figure 34 ). H igher amounts of
siRNA used in the transfections were determined to be cytotoxic at levels greater
than 4µg (data not included), probably due to the higher levels of RNAifect
required for complex formation . These results were similar to those observed by
Scherr et al. , who found that synthetic Bcr-Abl siRNA delivered using
electroporation sensitized Bcr-Ab/-positive BaF3 cells for treatment with Gleevec
(30).
In conclusion , this study suggested a correlation with transfection of K-562
cells with Bcr-Abl-specific siRNA and treatment with Gleevec. The results
showed that the effective dose of Gleevec was lowered greater than two-fold
when primed with Bcr-Abl-specific siRNA. While both siRNA preparations exhibit
this correlation, the synthetic siRNA preparation resulted in a greater reduction of
the mRNA. The synthetic Bcr-Abl siRNA required two transfections to down
regulate the Bcr-Abl protein, while the transcribed-digested showed no effect on
the Bcr-Abl protein. To corroborate the down-regulation of Bcr-Abl , Bcl-xL protein
levels were also reduced in K-562 cells transfected twice with synthetic Bcr-Abl
siRNA, suggesting that apoptosis sensitivity was restored .
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Figure 35. Proposed RNAi/Gleevec mechanism. The
proposed mechan ism of RNAi lowering the IC 50 of
Gleevec i nvolves the degradation of the Bcr-Abl transcript
by Bcr-Abl specific siRNA. The red uction of the Bcr-Abl
transcript leads to a red uction in the Bcr-Abl protein . With
less of the Bcr-Abl protein present, a lower dose of
Gleevec is required to inhibit proliferation.
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Proposed Further Stud ies

This project could lead to a variety of stud ies i nclud ing analyzing the RNAi
effect in K-562 sublines with varying copy nu mbers of Bcr-Abl as wel l as using
different Bcr-Abl-expressing cell lines to get a wider comparison . A study
applying RNAi in a Gleevec-resista nt K-562 cell line could provide some i nsight
on the mechanisms of drug resistance in CML. Another application cou ld involve
using Bcr-Abl mutants and measuring the efficacy of RNAi specific for Bcr-Abl.
Studies involving a dual RNAi approach using si RNA for both Bcl-xL and for Bcr
Abl could be analyzed to determine if there is an add itive relationship between
the two siRNAs .
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